Novartis AG (NVS) Financials
NVS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 99.9 billion | 53.2 billion |
2023-09-30 | 112.7 billion | 74.5 billion |
2023-06-30 | 111.0 billion | 59.0 billion |
2023-03-31 | 112.2 billion | 60.1 billion |
NVS Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 1.8 billion | 248.0 million |
2023-09-30 | 4.7 billion | 205.0 million |
2023-06-30 | 2.6 billion | 233.0 million |
2023-03-31 | 2.5 billion | 199.0 million |
NVS Net Income
Date | Net Income |
---|---|
2023-12-31 | 2.6 billion |
2023-09-30 | 1.5 billion |
2023-06-30 | 2.3 billion |
2023-03-31 | 2.3 billion |
NVS Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 14.0 billion | - | 1.8 billion |
2023-09-30 | 12.7 billion | 19.5 billion | 1.7 billion |
2023-06-30 | 11.2 billion | 19.8 billion | 1.8 billion |
2023-03-31 | 12.3 billion | 22.0 billion | 1.8 billion |
NVS Shares Outstanding
NVS Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 783.0 million | 2.6 billion | 3.4 billion | - |
2023-09-30 | 683.0 million | 3.9 billion | 3.1 billion | - |
2023-06-30 | 996.0 million | 2.5 billion | 3.7 billion | - |
2023-03-31 | 470.0 million | 2.8 billion | 3.4 billion | - |
NVS Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 11.8 billion | 3.0 billion |
2023-09-30 | 12.1 billion | 3.1 billion |
2023-06-30 | 13.9 billion | 4.3 billion |
2023-03-31 | 13.2 billion | 3.9 billion |
NVS
List: Challengers
Price: $97.44
Dividend Yield: 3.84%
Forward Dividend Yield: 3.88%
Payout Ratio: 92.13%
Dividend Per Share: 3.78 USD
Earnings Per Share: 4.10 USD
P/E Ratio: 24.72
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 1.7 million
Ebitda: 2.5 billionMarket Capitalization: 200.7 billion
Average Dividend Frequency: 1
Years Paying Dividends: 28
DGR3: 4.59%
DGR5: 5.70%
DGR10: 4.54%
DGR20: 9.41%